Baxter International Inc. filings document formal disclosures for a NYSE-listed medtech issuer with common stock and listed global notes. Recent 8-K reports furnish earnings releases, financial-condition updates, dividend declarations, Regulation FD stockholder-engagement materials, executive leadership changes, severance and change-in-control arrangements, and exhibits tied to material corporate actions.
The company’s proxy materials cover board governance, stockholder voting matters, executive compensation and pay-versus-performance disclosures. Debt-related filings describe senior note issuances, supplemental indentures, underwriting arrangements and tender offers, while recurring reports identify registered securities, capital-structure actions and governance controls relevant to Baxter’s medical-device and healthcare-products business.
Baxter International Inc. (BAX) lists Terence John Rogers, its EVP and CFO, with 0 shares of common stock held directly as of October 1, 2026. The entry reports a holding, not a purchase or sale.
BAXTER INTERNATIONAL INC (BAX) reported an initial ownership filing for Bernard Heine, who serves as AVP, Finance and Interim Chief Accounting Officer and Controller. He reports 32,840 shares of Baxter common stock held directly as of September 15, 2026, including shares from automatic reinvestment of dividends, with no purchases or sales reported in this filing.
BAXTER INTERNATIONAL INC (BAX) reported a Form 4 for James Teaff, President, CCS. On September 1, 2026, 750 shares of common stock were withheld at $25.48 per share to pay tax liabilities arising from the settlement of vested restricted stock units granted on September 1, 2023. Following this tax-withholding disposition, Teaff directly held 30,370 shares, including shares from automatic dividend reinvestment and the Baxter Employee Stock Plan.
BAXTER INTERNATIONAL INC (BAX) reported that President and CEO Andrew P. Hider had 54,276 shares of common stock withheld on September 2, 2026 to cover taxes due from the settlement of vested restricted stock units granted on September 2, 2025, at a reference price of $25.70 per share. Following this tax-withholding disposition, he directly holds 518,447 shares of Baxter common stock, which total includes the automatic reinvestment of dividends; no Rule 10b5-1 trading plan is reported.
BAXTER INTERNATIONAL INC (BAX) reported that executive Julie Foster, President, Front Line Care, had 2,098 shares of common stock withheld on September 2, 2026 to cover tax obligations arising from the settlement of vested restricted stock units granted on September 2, 2025, at a reference price of $25.70 per share. After this tax-withholding transaction, Foster directly holds 29,164 shares of Baxter common stock, a figure that includes the automatic reinvestment of dividends. No transactions were reported as being made under a Rule 10b5-1 trading plan.
Baxter International Inc. (BAX) announced a senior finance leadership transition, appointing John Rogers as Executive Vice President and Chief Financial Officer effective October 1, 2026. Rogers joins from Smith+Nephew plc, where he has served as CFO, and brings prior CFO and CEO experience at WPP plc and J Sainsbury plc.
His compensation package includes a $925,000 base salary, a target annual bonus equal to 100% of salary, a long-term equity target of $4,000,000 starting in 2027, two make-whole equity grants, and a $2,827,629 sign-on bonus subject to repayment if he departs within 24 months under specified conditions. Baxter is also putting short-term interim arrangements in place: CEO Andrew Hider will serve as interim CFO for roughly two weeks in September, and Assistant Controller Bernie Heine will become interim Chief Accounting Officer and Controller with additional pay and equity. Baxter reiterated its full-year 2026 financial outlook from its July 30, 2026 earnings announcement.
Baxter International Inc. (BAX) reported two major financing actions. First, it entered into Amendment No. 2 to its amended and restated five-year credit agreement. The amendment increases the maximum net leverage ratio covenant for five fiscal quarters through September 30, 2027 and removes Baxter World Trade SRL as a borrower, while leaving the rest of the credit agreement in place.
Second, Baxter detailed early results and pricing for its previously announced cash tender offers for four series of senior notes and increased the aggregate purchase price cap (the Offer Cap) from $500 million to $600 million. As of the Early Tender Time on August 17, 2026, holders had tendered $421.99 million of 3.132% notes due 2051, $132.199 million of 3.500% notes due 2046, $72.744 million of 4.500% notes due 2043 and $756.712 million of 2.539% notes due 2032. Baxter priced the offers using a waterfall acceptance methodology tied to U.S. Treasury benchmarks and expects to purchase Notes corresponding to a $600 million aggregate purchase price on the August 20, 2026 Early Settlement Date, including all tendered notes in the first three series and a prorated portion of the 2032 notes.
Baxter International Inc. disclosed that on July 31, 2026, Anita Zielinski notified the company of her decision to resign as Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller. The resignation will be effective September 15, 2026, as she plans to join another company.
The company states that Ms. Zielinski’s resignation is not due to any disagreement with management or the board regarding operations, policies, practices, financial disclosures or accounting matters. This represents a planned transition in Baxter’s senior finance and accounting leadership roles.
Baxter International Inc. has commenced cash tender offers to purchase for cash certain outstanding senior notes, using a “waterfall” process, for an aggregate purchase price of up to $500 million excluding accrued and unpaid interest (the “Offer Cap”). The offers cover four series: 3.132% Senior Notes due 2051, 3.500% Senior Notes due 2046, 4.500% Senior Notes due 2043 and 2.539% Senior Notes due 2032, each with its own acceptance priority level.
Holders who tender by the Early Tender Time of 5:00 p.m. New York City time on August 17, 2026 and whose notes are accepted receive “Total Consideration” that includes an Early Tender Premium of $30 per $1,000 principal. The offers expire at 5:00 p.m. New York City time on September 1, 2026, with early settlement expected on August 20, 2026 and final settlement on September 3, 2026. The offers are not conditioned on one another or on any minimum tender and remain subject to conditions described in the Offer to Purchase.